A new test may reveal which patients will respond to treatment for graft versus host disease , an often life-threatening complication of stem cell transplants used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue. Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive.
http://ift.tt/1A2i92F
http://ift.tt/1A2i92F
No comments:
Post a Comment